Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AZTA
AZTA logo

AZTA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Azenta Inc (AZTA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
19.220
1 Day change
3.50%
52 Week Range
41.730
Analysis Updated At
2026/05/08
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Azenta is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near short-term support but the broader trend is still bearish, recent earnings were weak, guidance was cut, and the latest news flow is clearly negative. With no AI Stock Picker or SwingMax signal and no strong turnaround confirmation, the better call is to avoid buying now.

Technical Analysis

AZTA is in a bearish technical setup. MACD histogram is negative and expanding, showing downside momentum. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms a downtrend. RSI_6 at 20.07 shows the stock is very oversold, but not yet giving a reliable reversal signal. Price at 18.58 is just below the first support level at 18.744, meaning the stock is testing support rather than breaking out. Overall, the chart favors caution over entry.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish from positioning because the put-call open interest ratio is low at 0.32, meaning calls outweigh puts. However, current option volume is extremely light, so this does not show strong active conviction. Implied volatility is elevated at 63.75 with IV percentile at 89.24, which suggests the market expects larger moves, likely around earnings/earnings aftermath. Net options sentiment is not strong enough to override the weak fundamentals and price trend.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
4

Positive Catalysts

  • ["Congress trading data shows 1 net purchase transaction and no sales in the last 90 days, which is a mildly positive signal.", "Analysts still maintain constructive ratings despite lower targets: Evercore ISI keeps Outperform and Jefferies keeps Buy.", "Open interest put-call ratio of 0.32 suggests positioning is not heavily bearish.", "The company is extending long-range plan targets to 2029, which may support a longer-term restructuring story if execution improves."]

Neutral/Negative Catalysts

  • ["Q2 fiscal 2026 earnings missed expectations, with non-GAAP EPS at -$0.04 versus $0.14 expected.", "Revenue came in at $145 million, and guidance was lowered for fiscal 2026 revenue and organic growth.", "Adjusted EBITDA fell sharply to $8 million and the company now expects margin pressure in fiscal 2026.", "A $149 million goodwill impairment charge and a related investigation have added major fundamental overhang.", "Recent news shows revenue from continuing operations declined and strategic execution remains challenged.", "The technical trend is bearish, and historical pattern data suggests negative short-term drift."]

Financial Performance

In Q2 fiscal 2026, Azenta reported revenue of $144.8 million, up 0.96% year over year, but profitability weakened sharply. Net income dropped to 0, EPS was -3.49, and gross margin fell to 42.84%, down 6.75% year over year. The latest quarter season is Q2 FY2026, and the overall picture is one of weak earnings quality, margin compression, and reduced guidance despite slight top-line growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts remain positive on the stock in rating terms but less optimistic on price targets. Evercore ISI lowered its target to $35 from $45 while keeping Outperform, and Jefferies cut its target to $35 from $40 while keeping Buy. This shows Wall Street pros still see upside over the long term, but they are clearly trimming expectations after the weaker acquisition impact and softer growth outlook. The pros view is constructive on strategy, but the cons are the earnings miss, guidance cuts, and execution risk.

Wall Street analysts forecast AZTA stock price to rise
6 Analyst Rating
Wall Street analysts forecast AZTA stock price to rise
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 18.570
sliders
Low
30
Averages
39.5
High
45
Current: 18.570
sliders
Low
30
Averages
39.5
High
45
Evercore ISI
Outperform
to
Outperform
downgrade
$45 -> $35
AI Analysis
2026-04-06
Reason
Evercore ISI
Price Target
$45 -> $35
AI Analysis
2026-04-06
downgrade
Outperform
to
Outperform
Reason
Evercore ISI lowered the firm's price target on Azenta to $35 from $45 and keeps an Outperform rating on the shares as part of the firm's medical technology and life science tools Q1 preview.
Jefferies
Matthew Stanton
Buy
to
Buy
downgrade
$40 -> $35
2026-04-01
Reason
Jefferies
Matthew Stanton
Price Target
$40 -> $35
2026-04-01
downgrade
Buy
to
Buy
Reason
Jefferies analyst Matthew Stanton lowered the firm's price target on Azenta to $35 from $40 and keeps a Buy rating on the shares. The firm is updating its model for the recent acquisition of UK Biocentre, noting that the deal is expected to be dilutive to adjusted EBITDA pro-forma for fiscal year in 2026 and accretive to 2027/28 organic revenue growth and adjusted EBITDA margin.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AZTA
Unlock Now

People Also Watch